Safety considerations for statins

Current Opinion in Lipidology

Volumn 13, Issue 6, 2002, Pages 637-644

  Bolego, Chiara ^a   Baetta, Roberta ^a   Bellosta, Stefano ^a   Corsini, Alberto ^a   Paoletti, Rodolfo ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Drug interactions; Myopathy; Pharmacokinetics; Rhabdomyolysis

Indexed keywords

ATORVASTATIN; BEZAFIBRATE; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; CYCLOSPORIN A; CYTOCHROME P450; DILTIAZEM; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LACIDIPINE; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; VERAPAMIL;

DRUG ABSORPTION; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MYOPATHY; PHARMACOGENOMICS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS;

ANTICHOLESTEREMIC AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MUSCULAR DISEASES; RHABDOMYOLYSIS; RISK FACTORS;

EID: 0036909541     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200212000-00007     Document Type: Review

References (71)

1. Randomised trial of choresterol lowering in 4444 patients with coronary head disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary head disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-1009.
4. Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary head disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339:1349-1357.
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-1622.
6. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360:7-22.
7. Serruys PWJC, de Feyter P, Macaya C, et al. for the Lescol Intervention Prevention Study investigators. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 2002; 256:3215-3222.
8. Davidson MH. Safety profiles for HMG-CoA reductase inhibitors. Drugs 2001; 61:1917-1926.
9. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Hardman GJ, Limbird LE, Goodman Gilman A, editors. The Pharmacological Basis of Therapeutics, 10th Ed. New York: McGraw Hill; 2001. pp. 971-1002.
10. Tomlinson B, Chan P, Lan W. How well tolerated are lipid-lowering drugs? Drugs Aging 2001; 18:665-683.
11. Baycol Web Site. Available at: http://www.baycol.com/Dear_HealthCare_-Letter_Baycol_pull.jpg. Accessed 20 November 2001.
12. Adult Treatment Panel III. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults. JAMA 2001; 285:2486-2493.
13. Furberg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovasc Med 2001; 2:205-207.
14. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002; 346:539-540.
15. Bruno-Joyce J, Dugas JM, MacCausland OE. Cerivastatin and gemfibrozil-associated rhamyolisis. Ann Pharmacother 2001; 35:1016-1019.
16. Lau TK, Leachman DR, Laufschanowski R. Severe rhabdomyolysis associated with the cerivastatin-gemfibrozil combination therapy: Report case. Tex Heart Inst J 2001; 28:142-145.
17. Garcia-Valdecasas-Campelo E, Gonzalez-Reimers E, Lopez-Lirola A, et al. Acute rhabdomyolysis associated with cerivastatin therapy. Arch Intern Med 2001; 161:893.
18. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother 2002; 36:288-295.
19. Pfeffer MA, Keech A, Sacks FM, et al. Safety and tolerability of pravastatin in long-term clinical trials: Prospective Pravastatin Pooling (PPP) Project. Circulation 2002; 105:2341-2346.
20. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-511.
21. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Safety 2000; 23:197-213.
22. Black DM. A general assessment of the safety of HMG CoA reductase inhibitors (statins). Curr Atheroscl Rep 2002; 4:34-41.
23. Dujovne CA. Side effects of statins: Hepatitis versus 'transaminitis'-myositis versus 'CPKitis'. Am J Cardiol 2002; 89:1411-1413.
24. Tolman KG. The liver and lovastatin. Am J Cardiol 2002; 89:1374-1380.
25. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001; 175:486-489.
26. Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: A population-based follow-up study. Epidemiology 2001; 12:565-569.
27. Lee AJ, Maddix DS. Rhabdomyolysis secondary to a drug interaction between simvastatin and clarithromycin. Ann Pharmacother 2001; 35:26-31.
28. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001; 35:908-917.
29. Benghozi R, Bortolini M, Jia Y, et al. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002; 89:231-233.
30. Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1995; 52:1639-1645.
31. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscl Supp 2002; 3:35-40.
32. Pierno S, De Luca A, Tricarico D, et al. Potential risk of myopathy by HMG CoA reductase inhibitors: A comparison of pravastatin and simvastatin effects on membrane electrical properties of rat skeletal muscle fibers. J Pharmacol Exp Ther 1995; 275:1490-1496.
33. Corsini A, Bellosta S, Baetta R, et al. New insights into pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther 1999; 84:413-428.
34. Sabia H, Prasad P, Smith HT, et al. Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia. J Cardiovasc Pharmacol 2001; 37:502-511.
35. Bogman K, Peyer AK, Torok M, et al. HMG-CoA reductase inhibitors and Pglycoprotein modulation. Br J Pharmacol 2001; 132:1183-1192.
36. Wang E, Casciano CN, Clement RP, et al. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm Res 2001; 18:800-806.
37. Siekmeier R, Lattke P, Mix C, et al. Dose dependency of fluvastatin pharmacokinetics in serum determined by reverse phase HPLC. J Cardiovasc Pharmacol Ther 2001; 6:137-145.
38. Ballantyne CM, Pazzucconi F, Pinto X, et al. Efficacy and tolerability of fluvastatin extended-release delivery system: A pooled analysis. Clin Ther 2001; 23:177-192.
39. Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John's Wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70:518-524.
40. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002; 16:569-577.
41. Gutierrez CA. Sildenafil-simvastatin interaction: Possible cause of rhabdomyolysis [Letter]? Am Fam Physician 2001; 63:636-637.
42. Amsden GW, Kuye O, Wei GCG. A study of the interaction potential of azithromycin and clarithromycin with atorvastatin in healthy volunteers. J Olin Pharmacol 2002; 42:444-449.
43. Briggs JD. Causes of death after renal transplantation. Nephron Dial Transplant 2001; 16:1545-1549.
44. Heerey A, Barry M, Ryan M, et al. The potential for drug interactions with statin therapy in Ireland. Irish J Med Sci 2000; 169:176-179.
45. Asberg A, Hartmann A, Fjeldsa E, et al. Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients. Am J Transplant 2001; 1:382-386.
46. Scripture CD, Pieper JA. Clinical pharmacokinetics of fiuvastatin. Clin Pharmacokinet 2001; 40:263-281.
47. Holdaas H, Desmond J. Nephrol Dial Transplant (in press).
48. Holdaas H, Fellstrom B, Holme I, et al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 2001; 8:63-71.
49. Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporine A in transplant recipients. Transplant Proc 1993; 25:2732-2734.
50. Goldberg R, Roth D. Evaluation of fluvastatin in the treatment of hypercholesterolemia in renal transplant recipients taking cyclosporine. Transplantation 1996; 62:1559-1564.
51. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am J Cardiol 1988; 62:28J-34J.
52. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001; 35:1096-1107.
53. Kyrklund C, Backman JT, Kivisto KT, et al. Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001; 69:340-345.
54. Prueksaritanont T, Zhao JJ, Ma B, et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther 2002; 301:1042-1051.
55. Pauciullo P, Borgnino C, Paoletti R, et al. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000; 150:429-436.
56. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89:672-678.
57. Reaven P, Witztum JL. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 1988; 109:597-598.
58. Schmassmann-Suhijar D, Bullingham R, Gasser R, et al. Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 1998; 351:1929-1930.
59. Kanathur N, Mathai MG, Byrd Jr RP, et al. Simvastatin-diltiazem drug interaction resulting in rhabdomyolysis and hepatitis. Tenn Med 2001; 94:339-341.
60. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem [Letter]. Nephron 2001; 89:117-118.
61. Yeo KR, Yeo WW. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br J Clin Pharmacol 2001; 51:461-470.
62. Azie NE, Brater DC, Becker PA, et al. The interaction of diltiazem with lovastatin and pravastatin. Clin Pharmacol Ther 1998; 64:369-377.
63. Gruer PJ, Vega JM, Mercuri MF, et al. Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin. Am J Cardiol 1999; 84:811-815.
64. Ziviani L, Da Ros L, Squassante L, et al. The effects of lacidipine on the steady/state plasma concentrations of simvastatin in healthy subjects. Br J Clin Pharmacol 2001; 51:147-152.
65. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: A systemic review. JAMA 2001; 286:2270-2279.
66. Maitland-van der Zee AH, Klungel OH, Stricker BH, et al. Genetic polymorphisms: Importance for response to HMG-CoA reductase inhibitors. Atherosclerosis 2002; 163:213-222.
67. Roden DM, George AL. The genetic basis of variability in drug responses. Nat Rev 2002; 1:37-44.
68. Mulder AB, van Lijf HJ, Bon MAM, et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin Pharmacol Ther 2001; 70:546-551.
69. Nordin C, Dahl ML, Eriksson M, Sjoberg S. Is the cholesterol lowering effect of simvastatin influenced by CYP2D6 polymorphism? Lancet 1997; 350:29-30.
70. Gonzales FJ, Nebert DW. Evolution of the P450 gene superfamily: Animal plant 'warfare', molecular drive and human genetic differences in drug oxidation. Trends Genet 1990; 6:182-186.
71. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of statins increases events rates in patients with acute coronary syndromes. Circulation 2002; 105:1446-1452.